Novartis United States Novartis Patient Assistance Foundation (NPAF) NPAF is an independent 501(c)(3) non-profit organization that provides Novartis medications free of cost to eligible patients who have limited or no prescription insurance coverage and cannot afford the cost of their medication....
In, EffectivenessSupport, PatientStrategy, MitigationBermangorvine, By Martin
At Novartis, we are united by a single purpose to reimagine medicine to improve and extend people’s lives.Drug delivery, service delivery, and the future of cancer care State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in phar...
Application for funding to help address health disparities Health disparities Patient resources Patients and caregivers Healthcare professionals Novartis pipeline Novartis clinical trials Adverse event reporting HCP resources Personalized and Precision Medicine Health Information Technology Resources ...
The spokeswoman also pointed to the Novartis-sponsored Glivec Patient Assistance Program (GIPAP), which served the CML treatment needs of approximately 75,000 people by September 2017. AT WHAT COST? One of the key problems behind the high prices is that "it is incredibly expensive to develop th...
Basel, December 3, 2018 - Novartis today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for AVXS-101, now known as Zolgensma (onasemnogene abeparvovec-xxxx)[1], an investigational gene replacement therapy for the...
Just as Novartis has delayed an FDA filing in prostate cancer, Exelixis is also awaiting more mature overall survival data for a combination of its Cabometyx and Roche's Tecentriq to submit an application. (Exelixis) Another prostate cancer trial has hit its main goal, and y...
Whether you're a patient, job seeker, health or media professional or investor, you can find the best way to contact us from the options below. General Contact General Contact 1 888 NOW NOVA (1 888 669 6682) Monday - Friday, 8:30 AM - 5:00 PM ET. ...
United States Patent Application 20150004191 Kind Code: A1 Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added....
This application claims the benefit of U.S. Provisional Application No. 62/545,907, filed Aug. 15, 2017, the entire contents of which are incorporated by reference. Claims: What is claimed is: 1.A cannula for use in ophthalmic surgical procedures comprising:a tubular section defining a passa...